Medidata announced that it is partnering with TransCelerate BioPharma
Medidata, a global provider of cloud-based solutions for clinical research in life sciences, announced that it is partnering with TransCelerate BioPharma on a project designed to inform the nonprofit organization’s efforts around risk-based monitoring.
The joint initiative features Medidata's operational data in the Medidata Clinical Cloud™ to provide metrics and analytics around TransCelerate's recommended methodology on RBM and help answer questions posed by the industry regarding the benefits and challenges associated with a risk-based approach to monitoring of clinical trial sites. The analysis will more rigorously assess the relative contribution of source document verification (SDV) to overall clinical data quality.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.